{"id":"W3112002107","doi":"10.1200/jco.20.01370","title":"Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Biotech; Juno Therapeutics; Pharmacyclics; Kite Pharma; Servier; Ionis Pharmaceuticals; Regeneron Pharmaceuticals; Array BioPharma; Legend Biotech; Celgene; Takeda Pharmaceuticals North America; Exelixis; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb; American Society of Clinical Oncology; GlaxoSmithKline","keywords":"Medicine; Multiple myeloma; Quality of life (healthcare); Internal medicine; Oncology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002874438,0.0004702431,0.00139972,0.0001213347,0.0002882165,0.0008193362,0.0004316315,0.0004083852,0.001206748],"category_scores_gemma":[0.002084012,0.0001722912,0.001224615,0.0002553368,0.0004536897,0.0004176831,0.00036022,0.00183112,0.0001563223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003811193,"about_ca_system_score_gemma":0.0006232538,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000290467,"about_ca_topic_score_gemma":0.0009509067,"domain_scores_codex":[0.9992223,0.0005327525,0.00005225879,0.00007111894,0.00006627635,0.00005529274],"domain_scores_gemma":[0.9981914,0.0004909705,0.0006752506,0.0001006112,0.0000485522,0.0004932153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7796347,0.01135222,0.08832309,0.0009675556,0.003354431,0.0001464321,0.0001808733,0.001635193,0.007359361,0.0002166096,0.001961533,0.1048681],"study_design_scores_gemma":[0.3739754,0.3237401,0.2869795,0.0003501768,0.003948607,0.0006807778,0.0002101603,0.003019206,0.002584235,0.0005523606,0.003900372,0.0000590323],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929381,0.005548615,0.0001518131,0.0003876699,0.00006499592,0.0001342373,0.0003345169,0.00001209066,0.0004278501],"genre_scores_gemma":[0.9971634,0.001139559,0.000277408,0.0003519658,0.0001180523,0.000230347,0.0005006788,0.000003360451,0.0002153297],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002874438,"threshold_uncertainty_score":0.01520163,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1781192389579719,"score_gpt":0.4677665170859054,"score_spread":0.2896472781279336,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}